EUVIMEDEUVIMED entdecken
Crossref

Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases

Carina A Dehner, Jorge Torres-Mora, Sounak Gupta, Benjamin R Kipp, Kevin C Halling, Shaoxiong Chen, Laura M Warmke, Michael Michal, Ali Alani, Wendong Yu, Krisztian Kovacs, Farres Obeidin und 4 weitere

Modern Pathology · 2024-02 · 37 (2) · 100400

DOI: 10.1016/j.modpat.2023.100400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024-02. Verfasst von Carina A Dehner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; Department of Pathology, Indiana University School of Medicine, I…. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: NCI NIH HHS, Mayo Clinic, Department of Radiology, Weill Cornell Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soft tissue sarcomas harboring EWSR1::PATZ1 are a recently recognized entity with variable morphology and a heterogeneous immunohistochemical profile. We studied 17 such tumors. The tumors occurred in 12 men and 5 women (median age, 50 years; range, 15-71 years), involved the thoracoabdominal soft tissues (14 cases; 82%), lower extremities (2 cases; 12%), and tongue (1 case; 6%), and ranged from 0.7 to 11.3 cm (median, 4.7 cm). All but 1 patient received complete surgical resection; 7 were also treated with neoadjuvant chemo/radiotherapy. All cases showed typical features of EWSR1::PATZ1 sarcoma, including uniform round to spindled cells, fibromyxoid matrix, fibrous bands, hyalinized vessels, and pseudoalveolar/microcystic spaces. Unusual features, seen in a subset of cases, included degenerative-appearing nuclear atypia, epithelioid cytomorphology, mature fat, abundant rhabdomyoblasts, high mitotic activity, and foci with increased cellularity and nuclear atypia. Positive immunohistochemical results were desmin (16/17, 94%), MyoD1 (13/14, 93%), myogenin (6/14, 43%), GFAP (10/10, 100%), S100 protein (15/17, 88%), SOX10 (7/13, 54%), keratin (10/17, 59%), CD99 (4/11, 36%), H3K27me3 (retained expression 9/9, 100%), p16 (absent expression 1/4, 25%), and p53 (wild type 3/3, 100%). Fusion events included EWSR1 exon 8::PATZ1 exon 1 (14/17, 82%), EWSR1 exon 9::PATZ1 exon 1 (2/17, 12%), and EWSR1 exon 7::PATZ1 exon 1 (1/17, 6%). No evaluated tumor had alterations of CDKN2A/B and/or TP53, or MDM2 amplification. Clinical follow-up (16 patients: median, 13.5 months; range, 1-77 months) showed distant metastases in 3 patients (1/3 at time of presentation) and no local recurrences. At the time of last follow-up, 14 patients were disease free, 1 was alive with disease, 1 was dead of disease (at 13 months), and 1 had an indeterminant pulmonary nodule. We conclude that the morphologic spectrum of EWSR1::PATZ1 is broader than has been previously appreciated. Although more long-term follow-up is needed, the prognosis of these very rare sarcomas may be more favorable than previously reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaSoft Tissue NeoplasmsMaleHumansFemaleMiddle AgedTranscription FactorsRNA-Binding Protein EWSS100 ProteinsPrognosisBiomarkers, TumorRepressor ProteinsKruppel-Like Transcription Factors

Stichwörter der Autor:innen

EWSR1::PATZ1 sarcomaimmunohistochemistrymolecular geneticssoft tissue sarcoma

Substanzen

Transcription FactorsRNA-Binding Protein EWSS100 ProteinsBiomarkers, TumorPATZ1 protein, humanRepressor ProteinsKruppel-Like Transcription FactorsEWSR1 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic; Biopticka Laboratory, Ltd, Plzen, Czech Republic.
  • Department of Pathology, Baylor University Medical Center, Dallas, Texas.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Förderung

  • NCI NIH HHS
  • Mayo Clinic
  • Department of Radiology, Weill Cornell Medical College

Zitieren

APA

Dehner, C. A., Torres-Mora, J., Gupta, S., Kipp, B. R., Halling, K. C., Chen, S., Warmke, L. M., Michal, M., Alani, A., Yu, W., Kovacs, K., Obeidin, F., Iwenofu, O. H., Satturwar, S., Meis, J. M., & Folpe, A. L. (2024). Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases. Modern Pathology, 37(2), 100400. https://doi.org/10.1016/j.modpat.2023.100400

Vancouver

Dehner CA, Torres-Mora J, Gupta S, Kipp BR, Halling KC, Chen S, et al. Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases. Modern Pathology. 2024;37(2):100400. doi:10.1016/j.modpat.2023.100400

BibTeX
@article{Dehner2024,
  author = {Dehner, Carina A and Torres-Mora, Jorge and Gupta, Sounak and Kipp, Benjamin R and Halling, Kevin C and Chen, Shaoxiong and Warmke, Laura M and Michal, Michael and Alani, Ali and Yu, Wendong and Kovacs, Krisztian and Obeidin, Farres and Iwenofu, Obiajulu Hans and Satturwar, Swati and Meis, Jeanne M and Folpe, Andrew L},
  title = {Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases},
  journal = {Modern Pathology},
  year = {2024},
  volume = {37},
  number = {2},
  pages = {100400},
  doi = {10.1016/j.modpat.2023.100400}
}
Kostenlos starten →